Co-Authors
                                
                                
                                    This is a "connection" page, showing publications co-authored by Paolo Ascierto and Gennaro Ciliberto.
                                
                                
                                
                                    
                                        
                                                
    
        
        
        
            Connection Strength
            
                
            
            1.760
         
        
        
     
 
    
        
        - 
            ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. Cancers (Basel). 2019 Sep 25; 11(10).
            
            
                Score: 0.211
            
         
        
        - 
            The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma. Expert Opin Ther Targets. 2019 01; 23(1):53-68.
            
            
                Score: 0.200
            
         
        
        - 
            Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). J Transl Med. 2018 07 21; 16(1):207.
            
            
                Score: 0.194
            
         
        
        - 
            Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. J Transl Med. 2017 11 16; 15(1):236.
            
            
                Score: 0.186
            
         
        
        - 
            The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. J Transl Med. 2017 11 03; 15(1):223.
            
            
                Score: 0.185
            
         
        
        - 
            MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 2017 Mar 28; 8(13):22262-22278.
            
            
                Score: 0.177
            
         
        
        - 
            miR-579-3p controls melanoma progression and resistance to target therapy. Proc Natl Acad Sci U S A. 2016 08 23; 113(34):E5005-13.
            
            
                Score: 0.170
            
         
        
        - 
            Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct 28; 12:277.
            
            
                Score: 0.150
            
         
        
        - 
            Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother. 2014 Jul; 63(7):675-83.
            
            
                Score: 0.144
            
         
        
        - 
            Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. J Exp Clin Cancer Res. 2018 Dec 17; 37(1):318.
            
            
                Score: 0.050
            
         
        
        - 
            Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells. J Exp Clin Cancer Res. 2017 Dec 08; 36(1):180.
            
            
                Score: 0.047
            
         
        
        - 
            Phenotype characterization of human melanoma cells resistant to dabrafenib. Oncol Rep. 2017 Nov; 38(5):2741-2751.
            
            
                Score: 0.046